Skip to main content
Andrew Bochner headshot

Andrew Bochner

FSA, MAAA
Principal & Consulting Actuary
New York, NY, US

Andrew Bochner is a principal and consulting actuary with the New York Atlanta Health Practice of Milliman. He joined the firm in 2014.

Download bioDownload

Experience

Andrew specializes in commercial health insurance pricing and filing and value-based contracting. His areas of expertise include:

  • Preparing commercial state and federal rate filings for both ACA and non-ACA products, including individual, small group, and large group
  • Providing actuarial support to health plans, including benchmarking, pricing, benefits compliance, reserving, and financial projections
  • Developing and evaluating risk contract frameworks and parameters between payers and providers
  • Analyzing healthcare utilization, costs, and trends for various clients using large commercial, Medicare, and Medicaid claims databases
  • Modeling various alternative payment risk-sharing strategies for payers, providers, and pharmaceutical manufacturers

Prior to joining Milliman, Andrew worked for a large consulting firm where he performed valuations for defined benefit pension plans, consulted on de-risking strategies for pension plans, and performed asset-liability studies to determine the optimal level of risk that pension plans should incorporate in their investments.

Publications

Read their latest work

Article

Designing an Episode-based Benefit Plan

30 September 2021 - by Dane Hansen, Andrew Bochner, Pamela M. Pelizzari
This report analyzes an Episode-based Benefit Plan (EBP) design that could be offered to members enrolled in commercial health plans.
Article

Implications of the COVID-19 pandemic on medical loss ratio for health plans

20 October 2020 - by Andrew Bochner, Jennifer Carioto, Luis Maldonado
How will COVID-19 affect a health plan’s medical loss ratio requirements in general and what are specific considerations for the commercial, Medicare Advantage, and Medicaid markets in 2020 and going forward?
Article

The preliminary reported impact of COVID-19 on ACA premiums

29 June 2020 - by Dane Hansen, Andrew Bochner, Emily DeAngelis
This paper examines the reported impact of COVID-19 on preliminary rate filings among six states and D.C. that have been publicly released as of June 15, 2020.
Article

The impact of California’s prescription drug cost-sharing cap

27 March 2018 - by Andrew Bochner, Gabriela Dieguez, Bruce S. Pyenson
This report analyzes the impact of the per-prescription cost-sharing cap for non-catastrophic plans on projected prescription drug spending across the California individual and small group markets.
Article

Open vs. minimally invasive hysterectomy: Commercially insured costs and readmissions

22 August 2016 - by Warner Huh, Andrew Bochner, Kate Fitch
This paper analyzes commercial payer differences in the average costs and readmission rates between inpatient open hysterectomies and three types of outpatient hysterectomies: laparoscopic, laparoscopic assisted, and vaginal.
Article

Cost differences between open and minimally invasive surgery

06 August 2016 - by Andrew Bochner, Tyler Engel, Kate Fitch
This study analyzes the difference in payer costs between minimally invasive surgery and open surgery in a commercial population for four commonly performed elective surgical procedures.
Article

An actuarial approach to the incremental cost of Hepatitis C in the absence of curative treatments

24 September 2015 - by Andrew Bochner, Ryan Cannon, Bruce S. Pyenson
HCV is the leading cause of both liver-related deaths and liver transplants in the United States. The high cost of new antiviral medicines has sparked debate over the cost of treating HCV, and some payers are seeking ways to minimize their spending on these medicines.